TABLE 1.
Baseline Characteristic Data per Group With Hematocrit, pH, Clot Formation Time, and Maximum Clot Firmness Following Hemodilution, Before Intervention Compared With Control Agent, CG
| Hemostatic Agent | CG (Control) | BL-IX | TAC | CS | CR | EP | XR | XS |
|---|---|---|---|---|---|---|---|---|
| Weight, kg | 41.4 ± 4.7 | 36.5 ± 3.6 | 41.3 ± 4.8 | 38.5 ± 5.4 | 39.0 ± 3.3 | 42 ± 5.3 | 41.6 ± 5.2 | 40.6 ± 6.3 |
| Hematocrit, % | 12.1 ± 1.8 | 12.6 ± 1.1 | 11 ± 2.1 | 12.5 ± 1.8 | 12.6 ± 1.4 | 12.2 ± 1.4 | 12.1 ± 1.4 | 11.6 ± 0.9 |
| pH | 7.20 ± 0.1 | 7.19 ± 0.1 | 7.22 ± 0.1 | 7.19 ± 0.1 | 7.26 ± 0.1 | 7.16 ± 0.1 | 7.23 ± 0.1 | 7.22 ± 0.0 |
| Clot formation time, s | 115 ± 37.3 | 110 ± 21.7 | 133.6 ± 33.8 | 120.3 ± 42.1 | 99.7 ± 17.8 | 176.9 ± 206 | 125.0 ± 29.2 | 116.1 ± 30.5 |
| Maximum clot firmness, mm | 52.0 ± 7.6 | 51.1 ± 5.6 | 41.3 ± 17.1 | 50.0 ± 6.9 | 53.7 ± 6.0 | 49.4 ± 12.8 | 48.8 ± 5.9 | 51.9 ± 4.3 |
CS, ChitoSAM 100; EP, EVARREST Fibrin Sealant Patch; TAC, TAC Wrapping Gauze; XR, ChitoGauze XR Pro.